Directorate Change
SkinBioTherapeutics PLC announced that Simon Hewitson, an Executive Director and Chief Operating Officer, will be leaving the company due to personal reasons. The recruitment process for his replacement has already begun. In the interim, CEO Stuart Ashman and Group Finance Director Emily Bertram will manage Hewitson's responsibilities. The company's Chair, Martin Hunt, acknowledged Hewitson's support, particularly with the divisional companies Bio-Tec Solutions and Dermatonics.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
14 October 2025 - the Board of Directors of SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces that Simon Hewitson, an Executive Director on the Board and Chief Operating Officer of the Group, will be stepping away from the Company on personal grounds. Recruitment for his successor has commenced. In the meantime, his duties are being managed by Stuart Ashman, CEO, and Emily Bertram, Group Finance Director.
Martin Hunt, Chair of SkinBioTherapeutics said: "Simon has been a good support to the business, particularly working with our divisional companies, Bio-Tec Solutions and Dermatonics. We wish him and his family well for the future."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.